Your browser doesn't support javascript.
loading
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system.
De la Cuadra-Grande, Alberto; Rioja-Zuazu, Jorge; Domínguez-Esteban, Mario; Torres, Esperanza; Blissett, Rob; Woodward, Emily; Oyagüez, Itziar; Fernández-Arjona, Manuel.
Afiliación
  • De la Cuadra-Grande A; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
  • Rioja-Zuazu J; Urology Department, Clínica Universitaria de Navarra, Navarra, Spain.
  • Domínguez-Esteban M; Urology Department, Hospital Marqués de Valdecilla, Cantabria, Spain.
  • Torres E; Health Economics & Market Access, Boston Scientific Inc, Madrid, Spain.
  • Blissett R; Health Economics & Economic Evaluation, MedTech Economics Ltd, Winchester, UK.
  • Woodward E; Health Economics & Market Access, Boston Scientific AG, Solothurn, Switzerland.
  • Oyagüez I; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
  • Fernández-Arjona M; Urology Department, Hospital Universitario del Henares, Madrid, Spain.
Expert Rev Pharmacoecon Outcomes Res ; 23(5): 499-510, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36897833
ABSTRACT

BACKGROUND:

Several surgical treatments are available for managing lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Water vapor thermal therapy (WVTT) is a new minimally invasive therapy. This study estimates the budget impact of introducing WVTT for LUTS/BPH into the Spanish health care system.

METHODS:

A model simulated the evolution of men over 45 years of age with moderate-severe LUTS/BPH after surgical treatment, over a 4-year time horizon, from the Spanish public health care service´s perspective. The technologies in scope included those most used in Spain WVTT, transurethral resection (TURP), photoselective laser vapourization (PVP) and holmium laser enucleation (HoLEP). Transition probabilities, adverse events and costs were identified from the scientific literature and validated by a panel of experts. Sensitivity analyses were performed by varying the most uncertain parameters.

RESULTS:

Per intervention, WVTT resulted in savings of €3,317, €1,933 and €2,661 compared to TURP, PVP and HoLEP. Over a 4-year time horizon, when performed in 10% of the cohort of 109,603 Spanish males with LUTS/BPH, WVTT saved €28,770,125 against the scenario without WVTT availability.

CONCLUSIONS:

WVTT could reduce the cost of managing LUTS/BPH, increase the quality of health care and reduce the length of procedure and hospital stay.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Síntomas del Sistema Urinario Inferior Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Síntomas del Sistema Urinario Inferior Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España